

The Undersigned hereby declares pursuant to 37 CFR § 1.10
that this correspondence is being deposited using Express Mail
Service Number EH 158641513 US in an envelope addressed to
Mail Stop Amendment, Commissioner for Patents,
PO Box 1450, Alexandria VA 22313-1450
on 3rd March, 2009

By: 

Printed: Matthew R. Kaser



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Sunil Shaunak et al.

Title: **GLYCOCODENDRIMERS AND THEIR THERAPEUTIC APPLICATIONS**

Serial No.: 10/511,317 Filing Date: 15th October, 2004

Examiner: TBA Group Art Unit: TBA

Mail Stop Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This communication is in response to the Restriction Requirement mailed 4th February, 2009, in the above-referenced application. This response is timely filed.

Restrictions

Claims 1 and 48-139 were originally filed. In the Office Action, the Examiner stated that restriction is required under 35 U.S.C. § 121 and § 372. In addition, the Examiner stated that the inventions are not so linked as to form a single inventive concept under PCT Rule 13.1 and in accordance with 37 C.F.R. § 1.499 requested Applicant to elect claims corresponding to one of the following inventions:

Group I Claims 1, 48-73, 78-87, and 92-102, drawn to a product of glycocendrimer.

Group II Claims 74-77, 88-91, 103-107, and 119-123 drawn to method of using the glycocendrimer product for the *in vivo* treatment.